Browsing by Author "McClure, Myra"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy
    (PLoS ONE, 2013) Stöhr, Wolfgang; Fidler, Sarah; McClure, Myra; Weber, Jonathan; Cooper, David; Ramjee, Gita; Kaleebu, Pontiano; Tambussi, Giuseppe; Schechter, Mauro; Babiker, Abdel; Phillips, Rodney E.; Porter, Kholoud; Frater, John
    A minority of HIV-1 positive individuals treated with antiretroviral therapy (ART) in primary HIV-1 infection (PHI) maintain viral suppression on stopping. Whether this is related to ART duration has not been explored. Design: And Methods: Using SPARTAC trial data from individuals recruited within 6 months of seroconversion, we present an observational analysis investigating whether duration of ART was associated with post-treatment viraemic control. Kaplan-Meier estimates, logistic regression and Cox models were used. 165 participants reached plasma viral loads (VL) 12 weeks compared to ≤12 weeks (p=0.061). Cumulative probabilities of remaining 12 weeks. In multivariable regression, ART for >12 weeks was independently associated with a lower probability of being ≥400 copies/ml within 12 weeks of ART stop (OR=0.11 (95%CI=0.03,0.34), p
  • Thumbnail Image
    Item
    Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum
    (Clinical Infectious Diseases, 2018) Lamorde, Mohammed; Wang, Xinzhu; Neary, Megan; Bisdomini, Elisa; Nakalema, Shadia; Byakika-Kibwika, Pauline; Mukonzo, Jackson K.; Khan, Waheed; Owen, Andrew; McClure, Myra; Boffito, Marta
    A clinical trial showed that efavirenz 400 mg once daily (EFV400) is as effective as the standard adult dose. World Health Organization recommends EFV400 as an alternative first-line agent, but data are lacking in the third trimester of pregnancy (TT). We investigated the pharmacokinetics, efficacy, and CYP2B6 pharmacogenetics in HIV-infected women (WLWH) on EFV400 during TT and post-partum (PP). Methods. An open-label 2-center study (United Kingdom, Uganda) was conducted in WLWH receiving antiretroviral regimens containing efavirenz 600 mg, who had their efavirenz dose reduced to EFV400. Weekly therapeutic drug monitoring (TDM), steadystate pharmacokinetic profiles (TT and PP), safety, virological efficacy, and CYP2B6 polymorphisms at positions 516 (C > T) and 938 (T > C) were evaluated.